scispace - formally typeset
D

Domenico Coppola

Researcher at University of South Florida

Publications -  274
Citations -  11942

Domenico Coppola is an academic researcher from University of South Florida. The author has contributed to research in topics: Cancer & Adenocarcinoma. The author has an hindex of 53, co-authored 274 publications receiving 10713 citations. Previous affiliations of Domenico Coppola include Moffitt Cancer Center.

Papers
More filters
Journal ArticleDOI

First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.

TL;DR: In vitro data indicate that the combination of capecitabine and temozolomide is synergistic for induction of apoptosis in neuroendocrine tumor cell lines.
Journal ArticleDOI

MicroRNA-221/222 negatively regulates estrogen receptor α and is associated with tamoxifen resistance in breast cancer

TL;DR: Findings indicate thatmiR-221 and miR-222 play a significant role in the regulation of ER α expression at the protein level and could be potential targets for restoring ERα expression and responding to antiestrogen therapy in a subset of breast cancers.
Journal Article

Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K.

TL;DR: Elevated kinase levels of AKT2 and phosphatidylinositol-3-OH kinase (PI3K) in 32 of 80 primary breast carcinomas indicate that regulation between the ERalpha and PI3K/AKT2 pathway may play an important role in pathogenesis of human breast cancer and could contribute to ligand-independent breast cancer cell growth.
Journal ArticleDOI

Molecular Staging for Survival Prediction of Colorectal Cancer Patients

TL;DR: Molecular staging identifies patient prognosis more accurately than the traditional clinical staging, particularly for intermediate Dukes' stage B and C patients, with the potential to direct adjuvant therapy.
Journal ArticleDOI

MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer.

TL;DR: Evidence is presented that miR-155 is a critical therapeutic target in breast cancer because of its role in regulation of cell survival and chemosensitivity through down-regulation of FOXO3a in breast cancers.